Bicara Therapeutics (NASDAQ:BCAX) Issues Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) issued its quarterly earnings results on Monday. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.29), FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Bicara says its pivotal FORTIFY-HN01 trial is on track for substantial enrollment by year-end, with an interim analysis planned in mid‑2027 to support potential accelerated approval of FICERA.
• Peer‑reviewed phase I‑B data (1,500 mg weekly + pembrolizumab) published in JCO showed deep, durable activity (median DOR 21.7 months; median OS 21.3 months) and the company will present 3‑year follow‑up across cohorts at ASCO.
• Bicara plans an alternative‑dosing randomized study (≈150–200 patients) starting in 3Q testing a 12‑week 1,500 mg weekly induction then either continued weekly or 2,250 mg every‑3‑weeks maintenance, with PFS as the primary endpoint to enable a more practical commercial regimen.
• Financially, the company ended Q1 with about $539.8M in cash and raised $161.8M (net) in February, providing runway into H1 2029, while warning operating expenses will rise as it funds the pivotal trial and builds commercial infrastructure.
• Management changes and commercial hires—Bill Schelman promoted to CMO and Alex Kharazi hired as CCO—signal preparations to transition from clinical stage to a commercial organization ahead of a potential launch.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock traded up $0.18 on Monday, hitting $22.76. The company had a trading volume of 277,093 shares, compared to its average volume of 510,235. The stock has a 50-day moving average of $20.52 and a 200-day moving average of $17.99. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $24.25. The firm has a market capitalization of $1.49 billion, a P/E ratio of -9.04 and a beta of -0.57.

Insider Activity at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $23.01, for a total value of $287,625.00. Following the sale, the chief operating officer directly owned 196,141 shares of the company’s stock, valued at approximately $4,513,204.41. The trade was a 5.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $22.88, for a total transaction of $125,840.00. Following the completion of the transaction, the insider directly owned 55,286 shares of the company’s stock, valued at approximately $1,264,943.68. The trade was a 9.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 174,310 shares of company stock valued at $3,459,283.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently bought and sold shares of BCAX. T. Rowe Price Investment Management Inc. grew its stake in shares of Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth $44,484,000. Vestal Point Capital LP boosted its holdings in Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. bought a new position in Bicara Therapeutics in the fourth quarter valued at $27,265,000. Finally, State Street Corp grew its position in Bicara Therapeutics by 179.5% in the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BCAX. Guggenheim assumed coverage on Bicara Therapeutics in a report on Monday. They issued a “buy” rating and a $42.00 price objective for the company. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Citizens Jmp reissued a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Bank of America began coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, HC Wainwright raised their price objective on Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.